Low-dose tirofiban is associated with reduced in-hospital mortality in cardioembolic stroke patients treated with endovascular thrombectomy

Whether tirofiban is safe and effective in cardioembolic stroke patients treated with endovascular thrombectomy (EVT) remains unknown; this study evaluated the safety and efficacy of low-dose tirofiban in this patients population. This study was a prospective registry study. Patients with cardioembo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 2021-08, Vol.427, p.117539-117539, Article 117539
Main Authors: Zhao, Wenbo, Xu, Jiali, Li, Sijie, Liu, Guiyou, Wu, Longfei, Li, Chuanhui, Wu, Chuanjie, Ren, Changhong, Chen, Jian, Duan, Jiangang, Wang, Ruixian, Song, Haiqing, Ma, Qingfeng, Ji, Xunming
Format: Article
Language:English
Subjects:
Cardioembolic stroke
Endovascular thrombectomy
Intracerebral hemorrhage
Tirofiban
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Whether tirofiban is safe and effective in cardioembolic stroke patients treated with endovascular thrombectomy (EVT) remains unknown; this study evaluated the safety and efficacy of low-dose tirofiban in this patients population. This study was a prospective registry study. Patients with cardioembolic stroke undergoing EVT from January 2013 to December 2020 were treated with EVT alone or EVT plus low-dose tirofiban. The primary outcome was symptomatic intracerebral hemorrhage (sICH) prior to discharge. The secondary outcomes included reocclusion, in-hospital mortality, and 3-month functional outcomes. Overall, 288 patients were recruited and 117 received low-dose tirofiban; 137 patients (47.6%) experienced ICH, 42 patients (14.6%) were sICH, and 23 patients (8%) were fatal ICH. Thirteen patients (11.1%) receiving tirofiban and 29 patients (17.0%) not receiving tirofiban experienced sICH (p = 0.167). Reocclusion occurred in nine patients (7.7%) receiving tirofiban and 15 patients (8.8%) not receiving tirofiban (p = 0.745). The rates of hernia (6.8% versus 20.5%) and decompressive craniectomy (2.6% versus 11.7%) were significantly lower in patients receiving tirofiban (p 
ISSN:0022-510X
1878-5883
DOI:10.1016/j.jns.2021.117539